1. Thalidomide-based Regimens: Rates of VTE* in Newly Diagnosed MM Treatment No Prophylaxis Any Prophylaxis ASA Warfarin 1-1.25 mg/d Prophylactic LMWH Therapeutic Anticoagulation T alone (95% CI) 1.3 (0.4–2.7) (n=380) NA 0.5 (0.4–0.6) (n=64) NA TD (95% CI) 4.1 (2.8–5.9) (n=628) 2.6 (2.1–3.2) (n=993) 2.3 (0.9–7.9) (n=80) 2.8 (2–3.9) (n=387) 2.1 (1.1–3.6) (n=446) 1.6 (0.2–4.1) (n=80) *per 100 patient-cycles ASA=aspirin; LMWH=low molecular weight heparin; MM=multiple myeloma; T=thalidomide; TD=thalidomide + dexamethasone; VTE=venous thromboembolism 1090

2. Thalidomide-based Regimens: Rates of VTE* in Previously Treated MM TreatmentNo prophylaxisASA Warfarin 1-1.25 mg/d Prophylactic LMWH Therapeutic Doses of Anticoagulation T alone (95% CI) 0.4 (0.2–0.8) (n=706) NA 0 (0–1.72) (n=17) NA T+ prednisone (95% CI) 0.6 (0.2–1.1) (n=258) NA TC (95% CI) 0.4 (0.01–1.2) (n=38) 0.4 (0.01–0.9) (n=37) NA TD (95% CI) 0.8 (0.1–2.1) (n=321) NA TDC agents (95% CI) 0.9 (0.3–1.8) (n=321) NA 2.4 (1.3–4) (n=102) NA 0 (0–2.2) (n=18) TDC including doxorubicin (95% CI) 6.7 (0.5–18.9) (n=331) NA 3.5 (1.2–6.5) (n=50) NA Lenalidomide-based regimens *per 100 patient-months ASA=aspirin; LMWH=low molecular weight heparin; MM=multiple myeloma; T=thalidomide; TC=thalidomide + cytotoxic chemotherapy; TD=thalidomide + dexamethasone; TDC=thalidomide + dexamethasone + cytotoxic chemotherapy; VTE=venous thromboembolism 1090

3. Lenalidomide-based Regimens Rates of VTE (per 100 patient-cycles) in patients with newly diagnosed MM TreatmentNo ProphylaxisAny ProphylaxisASA LD (95% CI) 0.8 (0.07–2) (n=278) 0.7 (0.5–1.1) (n=349) 0.9 (0.5–1.5) (n=172) Rate of VTE (per 100 patient-months) in patients with previously treated MM TreatmentNo ProphylaxisASA LD (95% CI) 0.7 (0.4–0.9) (n=361) NA LDC including doxorubicin (95% CI) NA 0.6 (0.01–2.1) (n=131) None of the studies reported major bleeding events. ASA=aspirin; LD=lenalidomide + dexamethasone; VTE=venous thromboembolism 1090